Nanoparticle-based passive drug targeting to tumors: Considerations and implications for optimization

Biological and Pharmaceutical Bulletin

Volumn 36, Issue 5, 2013, Pages 698-702

  Ogawara, Ken Ichi ^a   Yoshizawa, Yuta ^a   Un, Keita ^a   Araki, Tomoya ^a   Kimura, Toshikiro ^a   Higaki, Kazutaka ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Anti cancer drug; Endothelial cell; Nanoparticle; Passive targeting

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CREMOPHOR; DIMETHYL SULFOXIDE; DOXORUBICIN; LIPOSOME; MONOCLONAL ANTIBODY DC101; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; ORANTINIB; PACLITAXEL; PAZOPANIB; POLYETHYLENE; SEMAXANIB; SORAFENIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANAPHYLACTIC SHOCK; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CAPILLARY PERMEABILITY; CELL STRAIN C26; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM; DRUG EFFICACY; DRUG EXTRAVASATION; DRUG MEGADOSE; DRUG PENETRATION; DRUG RECEPTOR BINDING; DRUG RETENTION; DRUG SAFETY; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG TRANSPORT; DRUG TUMOR LEVEL; ENDOTHELIUM CELL; GENETIC STABILITY; HEMOLYSIS; HUMAN; HYPOXIA; LEWIS CARCINOMA; LOW DRUG DOSE; MELANOMA B16; MICROCIRCULATION; MULTIDRUG RESISTANCE; PASSIVE DRUG TARGETING; PH; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TISSUE PRESSURE; TUMOR CELL LINE; TUMOR MICROENVIRONMENT; TUMOR RESISTANCE; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOPARTICLES; NEOPLASMS; PERMEABILITY;

EID: 84876897551     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b13-00015     Document Type: Review

References (25)

1. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int. J. Pharm., 235, 179-192 (2002).
2. Zhang S, Liu X, Bawa-Khalfe T, Lu LS, Lyu YL, Liu LF, Yeh ET. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat. Med., 18, 1639-1642 (2012).
3. Araki T, Kono Y, Ogawara K, Watanabe T, Ono T, Kimura T, Higaki K. Formulation and evaluation of paclitaxel-loaded polymeric nanoparticles composed of polyethylene glycol and polylactic acid block copolymer. Biol. Pharm. Bull., 35, 1306-1313 (2012).
4. Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, McMeekin DS, Monk BJ, Rose PG. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol. Oncol., 96, 10-18 (2005).
5. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin. Cancer Res., 11, 4136-4143 (2005).
6. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392 (1986).
7. Iyer AK, Khaled G, Fang J, Maeda H. Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov. Today, 11, 812-818 (2006).
8. Ogawara K, Un K, Minato K, Tanaka K, Higaki K, Kimura T. Determinants for in vivo anti-tumor effects of PEG liposomal doxorubicin: importance of vascular permeability within tumors. Int. J. Pharm., 359, 234-240 (2008).
9. Saeki T, Tsuruo T, Sato W, Nishikawsa K. Drug resistance in chemotherapy for breast cancer. Cancer Chemother. Pharmacol., 56 (Suppl. 1), 84-89 (2005).
10. Levchenko A, Mehta BM, Niu X, Kang G, Villafania L, Way D, Polycarpe D, Sadelain M, Larson SM. Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. Proc. Natl. Acad. Sci. U.S.A., 102, 1933-1938 (2005).
11. Ogawara K, Un K, Tanaka K, Higaki K, Kimura T. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. J. Control. Release, 133, 4-10 (2009).
12. Folkman J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285, 1182-1186 (1971).
13. Kuhnert F, Tam BY, Sennino B, Gray JT, Yuan J, Jocson A, Nayak NR, Mulligan RC, McDonald DM, Kuo CJ. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc. Natl. Acad. Sci. U.S.A., 105, 10185-10190 (2008).
14. Ferrara N. Vascular endothelial growth factor as a target for anti-cancer therapy. Oncologist, 9 (Suppl. 1), 2-10 (2004).
15. Ichikawa K, Takeuchi Y, Yonezawa S, Hikita T, Kurohane K, Namba Y, Oku N. Antiangiogenic photodynamic therapy (PDT) using Visudyne causes effective suppression of tumor growth. Cancer Lett., 205, 39-48 (2004).
16. Kliche S, Waltenberger J. VEGF receptor signaling and endothelial function. IUBMB Life, 52, 61-66 (2001).
17. Mendel DB, Schreck RE, West DC, Li G, Strawn LM, Tanciongco SS, Vasile S, Shawver LK, Cherrington JM. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function. Clin. Cancer Res., 6, 4848-4858 (2000).
18. Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am. J. Pathol., 160, 985-1000 (2002).
19. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol., 156, 1363-1380 (2000).
20. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res., 62, 5381-5385 (2002).
21. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62 (2005).
22. Dickson PV, Hamner JB, Sims TL, Fraga CH, Ng CY, Rajasekeran S, Hagedorn NL, McCarville MB, Stewart CF, Davidoff AM. Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. Clin. Cancer Res., 13, 3942-3950 (2007).
23. Kano MR, Komuta Y, Iwata C, Oka M, Shirai YT, Morishita Y, Ouchi Y, Kataoka K, Miyazono K. Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature. Cancer Sci., 100, 173-180 (2009).
24. Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K. PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int. J. Pharm., 412, 132-141 (2011).
25. Yoshizawa Y, Ogawara KI, Fushimi A, Abe S, Ishikawa K, Araki T, Molema G, Kimura T, Higaki K. Deeper penetration into tumor tissues and enhanced in vivo antitumor activity of liposomal paclitaxel by pretreatment with angiogenesis inhibitor SU5416. Mol. Pharm., 9, 3486-3494 (2012).